Loading...
•
Dec 31, 2022
Evelo Q4 2022 Earnings Report
Evelo Biosciences reported financial results for Q4 2022 and provided business highlights.
Key Takeaways
Evelo Biosciences reported a net loss of $23.5 million for the fourth quarter of 2022, with cash and cash equivalents totaling $47.9 million as of December 31, 2022. The company progressed its SINTAX platform and clinical pipeline, with upcoming clinical milestones expected in 2023.
Continued progress on the SINTAX platform and clinical pipeline.
Demonstrated that SINTAX medicines generate systemically circulating regulatory T cells.
Developed a faster release capsule to improve drug substance exposure.
Initiated a Phase 2 study of EDP2939 in moderate plaque psoriasis patients, with results expected in the second half of 2023.
Evelo
Evelo
Forward Guidance
Evelo anticipates data from a fourth patient cohort of the Phase 2 study in atopic dermatitis evaluating the faster release capsule in 2Q 2023 and data from the Phase 2 portion of the trial with EDP2939 in psoriasis expected 2H 2023.